Entrada Therapeutics, Inc.

NasdaqGM TRDA

Entrada Therapeutics, Inc. Market Capitalization on January 14, 2025: USD 467.38 M

Entrada Therapeutics, Inc. Market Capitalization is USD 467.38 M on January 14, 2025, a 1.86% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Entrada Therapeutics, Inc. 52-week high Market Capitalization is USD 890.70 M on December 06, 2024, which is 90.58% above the current Market Capitalization.
Entrada Therapeutics, Inc. 52-week low Market Capitalization is USD 355.89 M on March 12, 2024, which is -23.85% below the current Market Capitalization.
Entrada Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 506.36 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGM: TRDA

Entrada Therapeutics, Inc.

CEO	Mr. Dipal Doshi
IPO Date	Oct. 29, 2021
Location	United States
Headquarters	6 Tide Street
Employees	177
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years